Unveiling unexpected adverse events and haemorrhagic safety: post-marketing safety surveillance of ramucirumab from the FAERS database

Hong Zhou; Tingting Chen; Ting Wei; Jinhua Zhang

doi:10.1080/17843286.2026.2655844

April 19, 2026Acta Clinica Belgica

Unveiling unexpected adverse events and haemorrhagic safety: post-marketing safety surveillance of ramucirumab from the FAERS database

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the safety profile of ramucirumab using post-marketing data.
Analyzed data from the FAERS database
Identified adverse events associated with ramucirumab
Examined signals related to haemorrhage
Detected unexpected adverse events linked to ramucirumab
Highlighted a new subgroup experiencing haemorrhage
Called for further investigation of these safety signals

Implication

Uncovers unexpected adverse events and safety concerns related to ramucirumab, suggesting the need for further examination.

Abstract

This study outlines the post-marketing safety profile of ramucirumab, identifying unexpected signals that warrant further investigation, including a newly described subgroup of ramucirumab-induced haemorrhage.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhou et al. (2026) studied this question.

synapsesocial.com/papers/69e865b56e0dea528ddea29f https://doi.org/10.1080/17843286.2026.2655844

View at Publisher

Ask AI

Bookmark

Share

Unveiling unexpected adverse events and haemorrhagic safety: post-marketing safety surveillance of ramucirumab from the FAERS database

Key Points

Implication

Abstract

Discussion

Cite This Study

Unveiling unexpected adverse events and haemorrhagic safety: post-marketing safety surveillance of ramucirumab from the FAERS database

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading